MedWatch

Novo Nordisk has begun phase III trial with antibody

Last summer, Novo Nordisk acquired the US-based biotech company Corvidia Therapeutics to access the antibody ziltivekimab. The pharmaceutical company has now commenced a phase III study of the drug, the company confirms in comment to MedWatch.

Photo: Stine Tidsvilde

In the beginning of September, Novo Nordisk started a phase III with the antibody ziltivekimab, which the company received in a million-dollar acquisition of the US-based company Corvidia Therapeutics last year, according to database Clinicaltrials.gov, which collects information about clinical studies, and Novo Nordisk confirms as much in comment to MedWatch.

According to the database, Novo Nordisk's intention with the phase III study, which has been named Zeus, is to test whether the substance ziltivekimab can reduce risk of cardiovascular events, such as heart attacks and strokes, in people suffering from cardiovascular disease, chronic kidney disease and inflammation.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs